Arandomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 971-979

  Siler, Thomas M ^a   Donald, Alison C ^b   O’Dell, Dianne ^b,c   Church, Alison ^b   Fahy, William A ^d  

^a GSK ^*  (United States)

^b GLAXOSMITHKLINE   (United States)

^c ASTRAZENECA   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

COPD; Health related quality of life; Long acting bronchodilator; SGRQ; Umeclidinium; Vilanterol

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; PLACEBO; SALBUTAMOL; UMECLIDINIUM PLUS VILANTEROL; BENZYL ALCOHOL DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHLOROBENZENE; DRUG COMBINATION; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE; UMECLIDINIUM; VILANTEROL;

ADULT; ARTICLE; BRONCHITIS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRY POWDER INHALER; EMERGENCY CARE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; LOWER RESPIRATORY TRACT INFECTION; LUNG CARCINOMA; LUNG FUNCTION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MINIMUM CLINICALLY IMPORTANT DIFFERENCE; MULTICENTER STUDY; PARANEOPLASTIC SYNDROME; PHARMACOLOGICAL PARAMETERS; PNEUMONIA; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYMPTOMATOLOGY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; AGED; CLINICAL TRIAL; CONVALESCENCE; DRUG COMBINATION; DRUG EFFECTS; EUROPE; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; ALBUTEROL; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EUROPE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INTENTION TO TREAT ANALYSIS; LUNG; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINUCLIDINES; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84970016223     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S102962     Document Type: Article

References (20)

1. GOLD. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2015. Available from: http://www.goldcopd.com/. Accessed March 10, 2015.
2. Gudmundsson G, Gislason T, Janson C, et al. Depression, anxiety and health status after hospitalisation for COPD: a multicentre study in the Nordic countries. Respir Med. 2006;100(1):87–93.
3. Hanania NA, Mullerova H, Locantore NW, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011;183(5):604–611.
4. Urff M, van den Berg JW, Uil SM, Chavannes NH, Damoiseaux RA. Depression and heart failure associated with clinical COPD questionnaire outcome in primary care COPD patients: a cross-sectional study. NPJ Prim Care Respir Med. 2014;24:14066.
5. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416–469.
6. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–1185.
7. Garcia-Aymerich J, Gomez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011;66(5):430–437.
8. GSK. ANORO™ ELLIPTA® prescribing information; 2014. Available from: https://www.gsksource.com/gskprm/htdocs/documents/ANORO-ELLIPTA-PI-MG.PDF. Accessed June 1, 2015.
9. GSK. ANORO™ ELLIPTA® summary of product characteristics; 2014. Available from: http://www.medicines.org.uk/emc/medicine/28949#INDICATIONS. Accessed June 1, 2015.
10. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–1546.
11. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects; 2008. Available from: http://www.wma.net/en/30publications/10policies/b3/17c.pdf. Accessed June 1, 2015.
12. Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946.
13. Jones PW. St George’s Respiratory Questionnaire: MCID. COPD. 2005;2(1):75–79.
14. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111–124.
15. Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312–1319.
16. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102(11):1511–1520.
17. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494.
18. Ismaila AS, Huisman EL, Punekar YS, Karabis A. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:2495–2517.
19. Cope S, Donohue JF, Jansen JP, et al. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res. 2013;14:100.
20. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–1546.